
PROFIT GUIDANCE FOR THE GROUP'S UNAUDITED CONDENSED INTERIM FINANCIAL STATEMENTS FOR THE SIX MONTHS AND FULL YEAR ENDED 31 DECEMBER 2025

The Board of Directors (the “**Board**”) of Pharmesis International Ltd. (the “**Company**”, together with its subsidiaries, collectively the “**Group**”) wishes to announce that after preliminary assessment of the Group’s unaudited condensed interim financial statements, the Board would like to inform the shareholders and investors that the Group is expected to report a net loss for the unaudited condensed interim financial statements for the six months and full year ended 31 December 2025 (“**FY2025**”).

The Group is in the process of finalising its financial results for FY2025 and further details of the Group’s financial performance will be disclosed when the Company announces its unaudited condensed interim financial statements for FY2025.

The Board wishes to advise its shareholders and investors to exercise caution when dealing with the shares of the Company. Shareholders and investors should consult with their stock brokers, bank managers, solicitors or other professional advisers if they have any doubt about the actions that they should take.

BY ORDER OF THE BOARD

Wu Xuedan
Executive Director and Chief Executive Officer
25 February 2026